VBI Vaccines Inc. (VBIV) - Earnings growth in current year

Official company branding of VBI Vaccines Inc. (VBIV)

The annual change in earnings per share illustrates the EPS trend, where the figure is fixed at 80.20. VBI Vaccines Inc. (VBIV) is forced to apply hidden discounts for insurance companies to compete for market share. Manufacturing plants in Canada and Israel ensure business stability. Growth prospects depend on the success of glioblastoma therapy and the expansion of hepatitis B vaccine sales.

VBIV VBI Vaccines, Inc. Net earnings per share growth this year (07/04/2022 - 08/17/2024)

Financial and market metric breakdowns for VBI Vaccines Inc. (VBIV)

Summary company analysis:VBI Vaccines (VBIV)
Finished products of VBI Vaccines Inc

This indicator reflects the annual trend of earnings per share, measuring the efficiency of business capitalization and the company's ability to generate net income. By analyzing the annual EPS change, an investor assesses the market consensus regarding profit growth rates compared to the previous period. For VBI Vaccines Inc. (VBIV), this metric depends directly on the success of R&D platforms and the ability to retain leading immunologists through a stock option system.